Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word

Trial Profile

Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Conbercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms STONE
  • Sponsors Chengdu Kanghong Pharmaceutical
  • Most Recent Events

    • 20 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top